Publications by authors named "Qinju He"
Article Synopsis
- The study reveals that the RNA methylation enzyme METTL3 is overexpressed in prostate cancer (PCa), correlating with poorer patient outcomes and establishing it as a potential oncoprotein.
- Researchers mapped the mA landscape in clinical samples and identified RRBP1 as a key target of METTL3, which enhances its stability in an mA-dependent way, contributing to aggressive PCa characteristics.
- The team developed two METTL3 peptide inhibitors that effectively reduce cancer cell growth in lab settings and tumor growth in animal models, highlighting a promising therapeutic avenue in targeting the METTL3/mA/RRBP1 signaling pathway.
Article Synopsis
- PRMT5 is a key protein involved in arginine methylation linked to various biological functions and is often overexpressed in aggressive prostate cancer (PCa), where it negatively impacts patient survival and promotes cancer growth.* -
- Inhibiting PRMT5 through genetic methods or drugs reduces cancer stemness and disrupts the cell cycle, demonstrating a stronger antitumor effect in more aggressive forms of PCa.* -
- Combining PRMT5 inhibitors with anti-PD-1 immunotherapy shows greater effectiveness against castration-resistant PCa, and a global CRISPR/Cas9 screen reveals potential for repurposing existing drugs to enhance treatment when used alongside PRMT5 inhibitors.*
Article Synopsis
- Prostate cancer exhibits significant histopathological diversity, and a new subtype identified as small cell-like PCa (SCLPC) shows aggressive clinical behavior with low androgen receptor activity but high stemness and proliferation.
- This subtype is characterized by a molecular profile associated with protein translation, including overexpression of ribosomal protein genes and SP1, a transcription factor linked to castration-resistant PCa (CRPC).
- Targeted therapies like the SP1 inhibitor plicamycin and the translation elongation inhibitor homoharringtonine demonstrate potential in reducing CRPC growth and progression, highlighting these pathways as promising avenues for clinical treatment.
The molecular mechanisms underpinning prostate cancer (PCa) progression are incompletely understood, and precise stratification of aggressive primary PCa (pri-PCa) from indolent ones poses a major clinical challenge. Here, we comprehensively dissect, genomically and transcriptomically, the mA ( -methyladenosine) pathway as a whole in PCa. Expression, but not the genomic alteration, repertoire of the full set of 24 mA regulators at the population level successfully stratifies pri-PCa into three mA clusters with distinct molecular and clinical features.
View Article and Find Full Text PDFResveratrol attenuates diabetes-associated cell centrosome amplification via inhibiting the PKCα-p38 to c-myc/c-jun pathway.
Acta Biochim Biophys Sin (Shanghai)
January 2020
Type 2 diabetes increases the risk for cancer. Centrosome amplification can initiate tumorigenesis. We have described that type 2 diabetes increases the centrosome amplification of peripheral blood mononuclear cells, with high glucose, insulin, and palmitic acid as the triggers, which suggests that centrosome amplification is a candidate biological mechanism linking diabetes to cancer.
View Article and Find Full Text PDF